Jasper Therapeutics

Q2 FY2026 EarningsQ2 FY26 net loss of $2.8M (EPS -$0.10) significantly beat the consensus net loss of $10.6M (EPS -$0.31), primarily driven by a $3.98M non-cash gain from warrant liability revaluation. Operating expenses were $9.2M, approximately 18% lower than the expected EBIT loss of $11.3M, reflecting disciplined R&D and G&A spending. Following the July acquisition of Kira Pharmaceuticals and a concurrent $132M PIPE financing, management guides for a cash runway extending through H2 2028, substantially derisking the mid-term clinical pipeline execution.